HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Bupivacaine (USAN:INN:BAN)

HCID 2474
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
2180-92-9
Standard SMILES
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
InChIKey
LEBVLXFERQHONN-UHFFFAOYSA-N
Molecular formula
C18H28N2O
Average molar mass
288.4 g/mol
Monoisotopic mass
288.22016352

Overview

1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide is a piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline. It is a piperidinecarboxamide, a tertiary amino compound and an aromatic amide. It is a conjugate base of a 1-butyl-2-[(2,6-dimethylphenyl)carbamoyl]piperidinium.

Names & identifiers

Preferred name
Bupivacaine (USAN:INN:BAN)
IUPAC
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
English name
Bupivacaine
Molecular formula
C18H28N2O
Molecular weight
288.43

Names & synonyms

Bupivacaine (USAN:INN:BAN)Bupivacaine [USAN:INN:BAN]2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (+-)-RefChem:1080208bupivacaine1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide2180-92-938396-39-3DL-BupivacaineBupivacainaAnekainBupivacainum
Show more names
BUPIVACAINE BASEMARCAINELevobupivacaine (Bupivacaine)1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamideLAC-43win11318WIN 11318Carbostesin
(+-)-Bupivacaine1-Butyl-2',6'-pipecoloxylidideExparelBupivacainum [INN-Latin]Bupivacaina [INN-Spanish]dl-1-Butyl-2',6'-pipecoloxylidide(+/-)-BupivacaineAH 250

Database identifiers

CAS
2180-92-9、38396-39-3
PubChem CID
2474
DTXSID
DTXSID2022703

Properties

Computed structural properties

XLogP
3.4
Topological polar surface area
32.3 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
2
Rotatable bonds
5
Heavy atoms
21
Formal charge
0
Complexity
321

Experimental & physicochemical properties

DrugsPharmaceuticals
LogP · 2 items

3.6

3.35

Solubility9.77e-02 g/L
Human DrugsPharmaceuticals
Animal DrugsPharmaceuticals -> UK Veterinary Medicines Directorate List
Melting Point · 2 items

107-108 °C

107 - 108 °C

Physical DescriptionSolid
Dissociation Constants8.1
Collision Cross Section · 2 items

173.1 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

180.07 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Toxicology

Treatment · 1 item

If the compound has been ingested, rapid gastric lavage should be performed using 5% sodium bicarbonate. For skin contact, the skin should be washed with soap and water. If the compound has entered the eyes, they should be washed with large quantities of isotonic saline or water. In serious cases, atropine and/or pralidoxime should be administered. Anti-cholinergic drugs work to counteract the effects of excess acetylcholine and reactivate AChE. Atropine can be used as an antidote in conjunction with pralidoxime or other pyridinium oximes (such as trimedoxime or obidoxime), though the use of '-oximes' has been found to be of no benefit, or possibly harmful, in at least two meta-analyses. Atropine is a muscarinic antagonist, and thus blocks the action of acetylcholine peripherally.

Health Effects · 1 item

Acute exposure to cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Accumulation of ACh at motor nerves causes overstimulation of nicotinic expression at the neuromuscular junction. When this occurs symptoms such as muscle weakness, fatigue, muscle cramps, fasciculation, and paralysis can be seen. When there is an accumulation of ACh at autonomic ganglia this causes overstimulation of nicotinic expression in the sympathetic system. Symptoms associated with this are hypertension, and hypoglycemia. Overstimulation of nicotinic acetylcholine receptors in the central nervous system, due to accumulation of ACh, results in anxiety, headache, convulsions, ataxia, depression of respiration and circulation, tremor, general weakness, and potentially coma. When there is expression of muscarinic overstimulation due to excess acetylcholine at muscarinic acetylcholine receptors symptoms of visual disturbances, tightness in chest, wheezing due to bronchoconstriction, increased bronchial secretions, increased salivation, lacrimation, sweating, peristalsis, and urination can occur. Certain reproductive effects in fertility, growth, and development for males and females have been linked specifically to organophosphate pesticide exposure. Most of the research on reproductive effects has been conducted on farmers working with pesticides and insecticdes in rural areas. In females menstrual cycle disturbances, longer pregnancies, spontaneous abortions, stillbirths, and some developmental effects in offspring have been linked to organophosphate pesticide exposure. Prenatal exposure has been linked to impaired fetal growth and development. Neurotoxic effects have also been linked to poisoning with OP pesticides causing four neurotoxic effects in humans: cholinergic syndrome, intermediate syndrome, organophosphate-induced delayed polyneuropathy (OPIDP), and chronic organophosphate-induced neuropsychiatric disorder (COPIND). These syndromes result after acute and chronic exposure to OP pesticides.

Chemistry & industry

Pharmacology

ATC CodeN01BB01
Protein BindingBupivacaine is ~95% protein bound.
Pharmacodynamics · 1 item

Bupivacaine is a widely used local anesthetic agent. Bupivacaine is often administered by spinal injection prior to total hip arthroplasty. It is also commonly injected into surgical wound sites to reduce pain for up to 20 hours after surgery. In comparison to other local anesthetics it has a long duration of action. It is also the most toxic to the heart when administered in large doses. This problem has led to the use of other long-acting local anaesthetics:ropivacaine and levobupivacaine. Levobupivacaine is a derivative, specifically an enantiomer, of bupivacaine. Systemic absorption of local anesthetics produces effects on the cardiovascular and central nervous systems. At blood concentrations achieved with therapeutic doses, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal. However, toxic blood concentrations depress cardiac conduction and excitability, which may lead to atrioventricular block, ventricular arrhythmias and to cardiac arrest, sometimes resulting in fatalities. In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure. Following systemic absorption, local anesthetics can produce central nervous system stimulation, depression or both.

Mechanism of Action · 1 item

Like [lidocaine], bupivacaine is an amide local anesthetic that provides local anesthesia through blockade of nerve impulse generation and conduction. These impulses, also known as action potentials, critically depend on membrane depolarization produced by the influx of sodium ions into the neuron through voltage-gated sodium channels. Bupivacaine crosses the neuronal membrane and exerts its anesthetic action through blockade of these channels at the intracellular portion of their pore-forming transmembrane segments. The block is use-dependent, where repetitive or prolonged depolarization increases sodium channel blockade. Without sodium ions passing through the channel’s pore, bupivacaine stabilizes the membrane at rest and therefore prevents neurotransmission. In general, the progression of anesthesia is related to the diameter, myelination and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone. While it is well-established that the main action of bupivacaine is through sodium channel block, additional analgesic effects of bupivacaine are thought to potentially be due to its binding to the prostaglandin E2 receptors, subtype EP1 (PGE2EP1), which inhibits the production of prostaglandins, thereby reducing fever, inflammation, and hyperalgesia.

Related reactions

12 records
New reaction record
HRID 41862 reaction equation
HRID 41862As product
HRID 53078 reaction equation
HRID 53078As reactant
HRID 896949 reaction equation
HRID 896949As reactant
HRID 1057260 reaction equation
HRID 1057260As reactant
HRID 1059477 reaction equation
HRID 1059477As reactant
HRID 1352188 reaction equation
HRID 1352188As product
HRID 1699646 reaction equation
HRID 1699646As product
HRID 1886742 reaction equation
HRID 1886742As product
PreviousPage 1 of 2

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
ChEMBL
CHEMBL1098
ChEBI
CHEBI:77431
UNII
Y8335394RO
Nikkaji
J7.351B
Melting point
107.5 · 107.5-108°
Boiling point
430.65 °C · 430.65°C (rough estimate)
Density
1.0238 · 1.0238 (rough estimate)
refractive index
1.57 · 1.5700 (estimate)
pka
8.09 · 8.09; also reported as 8.17(at 25℃)
Water Solubility
101.5 mg/L · 101.5mg/L(25 ºC)
InChI
InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)
InChIKey
LEBVLXFERQHONN-UHFFFAOYSA-N
SMILES
C1(CCCCN1CCCC)C(=O)NC1C(C)=CC=CC=1C
CAS DataBase Reference
2180 · 2180-92-9(CAS DataBase Reference)
EWG's Food Scores
1 · 1
NCI Dictionary of Cancer Terms
Marcaine
FDA UNII
8335394 RO · Y8335394RO
NCI Drug Dictionary
Marcaine
ATC code
1 BB01,N01BB51 · N01BB01,N01BB51
NIST Chemistry Reference
2 · 2-Piperidinecarboxamide, 1-butyl-n-(2,6-dimethylphenyl)-(2180-92-9)
EPA Substance Registry System
2 · 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)- (2180-92-9)
Symbol(GHS)
7 · GHS07,GHS05,GHS06
Signal word
Danger
Hazard statements
315 · H315-H310-H318-H330-H300
Precautionary statements
262 · P262-P264-P270-P280-P302+P350-P310-P322-P361-P363-P405-P501-P264-P280-P302+P352-P321-P332+P313-P362-P280-P305+P351+P338-P310-P264-P270-P301+P310-P321-P330-P405-P501-P260-P271-P284-P304+P340-P310-P320-P403+P233-P405-P501
Hazard Codes
T+
Risk Statements
26 · 26/27/28-38-41
Safety Statements
22 · 22-26-36/37/39-45
RIDADR
2811 · 2811
Exposure Routes · 1 item

Epidural, Intraspinal, Infiltration. The rate of systemic absorption of local anesthetics is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic solution.

Toxicity Summary · 1 item

Bupivacaine is a cholinesterase or acetylcholinesterase (AChE) inhibitor. A cholinesterase inhibitor (or 'anticholinesterase') suppresses the action of acetylcholinesterase. Because of its essential function, chemicals that interfere with the action of acetylcholinesterase are potent neurotoxins, causing excessive salivation and eye-watering in low doses, followed by muscle spasms and ultimately death. Nerve gases and many substances used in insecticides have been shown to act by binding a serine in the active site of acetylcholine esterase, inhibiting the enzyme completely. Acetylcholine esterase breaks down the neurotransmitter acetylcholine, which is released at nerve and muscle junctions, in order to allow the muscle or organ to relax. The result of acetylcholine esterase inhibition is that acetylcholine builds up and continues to act so that any nerve impulses are continually transmitted and muscle contractions do not stop. Among the most common acetylcholinesterase inhibitors are phosphorus-based compounds, which are designed to bind to the active site of the enzyme. The structural requirements are a phosphorus atom bearing two lipophilic groups, a leaving group (such as a halide or thiocyanate), and a terminal oxygen.

Signs and Symptoms · 1 item

Recent clinical data from patients experiencing local anesthetic induced convulsions demonstrated rapid development of hypoxia, hypercarbia, and acidosis with bupivacaine within a minute of the onset of convulsions. These observations suggest that oxygen consumption and carbon dioxide production are greatly increased during local anesthetic convulsions and emphasize the importance of immediate and effective ventilation with oxygen which may avoid cardiac arrest.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Toxicity DataThe mean seizure dosage of bupivacaine in rhesus monkeys was found to be 4.4 mg/kg with mean arterial plasma concentration of 4.5 mcg/mL. LD50: 6 to 8 mg/kg (intravenous, mice) LD50: 38 to 54 mg/kg (subcutaneous, mice)

Safety data

ridadr
2811
risk_code
26/27/28-38-41
Signal word
Danger
Symbol(GHS)
GHS07,GHS05,GHS06
hazard_code
T+
safety_code
22-26-36/37/39-45
Hazard statements
H315-H310-H318-H330-H300
Precautionary statements
P262-P264-P270-P280-P302+P350-P310-P322-P361-P363-P405-P501-P264-P280-P302+P352-P321-P332+P313-P362-P280-P305+P351+P338-P310-P264-P270-P301+P310-P321-P330-P405-P501-P260-P271-P284-P304+P340-P310-P320-P403+P233-P405-P501
Biological Half-Life2.7 hours in adults and 8.1 hours in neonates. Bupivacaine applied together with [meloxicam] for postsurgical analgesia had a median half-life of 15-17 hours, depending on dose and application site.
Metabolism/Metabolites · 2 items

Amide-type local anesthetics such as bupivacaine are metabolized primarily in the liver via conjugation with glucuronic acid. The major metabolite of bupivacaine is 2,6-pipecoloxylidine, which is mainly catalyzed via cytochrome P450 3A4.

Amide-type local anesthetics such as bupivacaine are metabolized primarily in the liver via conjugation with glucuronic acid. The major metabolite of bupivacaine is 2,6-pipecoloxylidine, which is mainly catalyzed via cytochrome P450 3A4. Route of Elimination: Only 6% of bupivacaine is excreted unchanged in the urine. Half Life: 2.7 hours in adults and 8.1 hours in neonates

Absorption, Distribution and Excretion · 2 items

Systemic absorption of local anesthetics is dose- and concentration-dependendent on the total drug administered. Other factors that affect the rate of systemic absorption include the route of administration, blood flow at the administration site, and the presence or absence of epinephrine in the anesthetic solution. Bupivacaine formulated for instillation with [meloxicam] produced varied systemic measures following a single dose of varying strength. In patients undergoing bunionectomy, 60 mg of bupivacaine produced a Cmax of 54 ± 33 ng/mL, a median Tmax of 3 h, and an AUC∞ of 1718 ± 1211 ng\*h/mL. For a 300 mg dose used in herniorrhaphy, the corresponding values were 271 ± 147 ng/mL, 18 h, and 15,524 ± 8921 ng\*h/mL. Lastly, a 400 mg dose used in total knee arthroplasty produced values of 695 ± 411 ng/mL, 21 h, and 38,173 ± 29,400 ng\*h/mL.

Only 6% of bupivacaine is excreted unchanged in the urine.

Cellular LocationsExtracellular
Metabolite PathwaysBupivacaine Action Pathway

Uses & manufacturing

UsesFor the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.
Use ClassificationPharmaceuticals
Applications · 3 items

UsesAnesthetic (local).

UsesLike lidocaine and mepivacaine, bupivacaine is used in infiltration, spinal, and epidural anesthesia in blocking nerve transmission. Its most distinctive property is its long-lasting action. It is used for surgical intervention in urology and in lower thoracic surgery from 3 to 5 h in length, and in abdominal surgery lasting from 45 to 60 min. It is used to block the trifacial nerve, the sacral and brachial plexuses, in resetting dislocations, in epidural anesthesia, and during Cesarian sections.

General DescriptionBupivacaine was synthesized simultaneously with mepivacainein 1957 but was at first overlooked because of the increasedtoxicity compared with mepivacaine. When themethyl on the cyclic amine of mepivacaine is exchanged fora butyl group the lipophilicity, potency and the duration ofaction all increase. Literature reports of cardiovascular toxicity,including severe hypotension and bradycardia, areabundant in the literature.91 Bupivacaine is highly bound toplasma proteins (95%), and thus the free concentration mayremain low until all of the protein binding sites are occupied.After that point, the plasma levels of bupivacaine rise rapidlyand patients may progress to overt cardiac toxicity withoutever showing signs of CNS toxicity. The cardiotoxicity ofbupivacaine is a result of its affinity to cardiac tissues and itsability to depress electrical conduction and predispose theheart to reentry types of arrhythmias. The cardiotoxicity ofbupivacaine was found to be significantly more prominentwith the “R” isomer, or the racemic mixture, thus the “S”stereoisomer is now on the market as levobupivacaine.

Upstream & downstream products

Upstream raw materials

Ethyl 2-bromo-6-chlorohexanoateHexanoic acidButylamineEthyl pipecolinate2,6-DimethylanilineDiethyl malonateNitrosyl chlorideFormic acid1-BromobutaneZINC4-Bromo-2,6-dimethylaniline
Additional notes · 1 item

DefinitionChEBI: 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide is a piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline. It is a piperidinecarboxamide, an aromatic amide and a tertiary amino compound. It is a conjugate base of a 1-butyl-2-[(2,6-dimethylphenyl)carbamoyl]piperidinium.